Results 1 to 10 of about 5,703,192 (247)

Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Prior national data showed a substantial in‐hospital mortality in septal myectomy (SM) with an inverse volume–outcomes relationship. This study sought to assess the contemporary outcomes of septal reduction therapy and volume–outcome ...
Ahmed M. Altibi, Fares Ghanem, Yuanzi Zhao, Miriam Elman, Joaquin Cigarroa, Babak Nazer, Howard K. Song, Ahmad Masri   +7 more
doaj   +4 more sources

Septal Reduction Therapy for Obstructive Hypertrophic Cardiomyopathy: Volume Still Matters for Septal Myectomy [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Vincent Y. See, Libin Wang
doaj   +4 more sources

Optimal Medical Therapy Versus Septal Reduction Therapy [PDF]

JACC: Advances
Francis Joshua Beloy, MD MBA, Jillian Reeze Medina, MD, Ralf Martz Sulague, MD MS, Jacques Kpodonu, MD   +3 more
doaj   +4 more sources

Alcohol Septal Ablation or Septal Myectomy? An Updated Systematic Review and Meta-Analysis of Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy [PDF]

Frontiers in Cardiovascular Medicine, 2022
ObjectiveTo evaluate the safety and effectiveness of alcohol septal ablation (ASA) and septal myectomy (SM) for the treatment of hypertrophic obstructive cardiomyopathy.MethodsWe searched the PubMed, MEDLINE, EMBASE, and CBM databases for observational ...
Xifeng Zheng, Bin Yang, Haosheng Hui, Bing Lu, Yinhui Feng   +4 more
doaj   +2 more sources

The Risk of Ventricular Arrhythmias between Alcohol Septal Ablation and Septal Myectomy in Hypertrophic Cardiomyopathy: A Meta-Analysis on Septal Reduction Therapy [PDF]

Reviews in Cardiovascular Medicine, 2022
Background: Alcohol septal ablation (ASA) has been more commonly applied in medical refractory hypertrophic obstructive cardiomyopathy (HOCM) compared with septal myectomy (SM), however its potential to create a proarrhythmic substrate is increased ...
Wei Tang, Menghui Liu, Jie Li, Rongxuan Chang, Chen Su, Xiaoyu Zhang, Lichun Wang   +6 more
doaj   +2 more sources

Access Challenges for Septal Reduction Therapy Among Individuals With Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background In symptomatic patients with treatment‐refractory obstructive hypertrophic cardiomyopathy, septal reduction therapy (SRT) is recommended to relieve obstruction. This study examined the challenges associated with SRT access in the United States.
Anjali T. Owens, Patricia Schuler, Jenny Jiang, Xu Han, Ervant Maksabedian Hernandez, Amy Anderson, Yiyu Fang, Andrea Steffens, Anandkumar Dubey   +8 more
doaj   +2 more sources

Real-World Experience With Mavacamten in SRT-Eligible Obstructive HCM [PDF]

JACC: Advances
Background: Mavacamten, a cardiac myosin inhibitor, has been shown to improve symptoms and reduce left ventricular outflow tract gradients in obstructive hypertrophic cardiomyopathy (oHCM). However, real-world data regarding longer-term clinical outcomes,
Lusha W. Liang, MD, MS, Hiroo Takayama, MD, PhD, Tamim M. Nazif, MD, Linda Gojcaj, PA-C, Yuichi J. Shimada, MD, MPH, Shepard D. Weiner, MD   +5 more
doaj   +2 more sources

Fabry cardiomyopathy presenting as hypertrophic phenotype with left ventricular outflow tract obstruction: a case series [PDF]

Frontiers in Cardiovascular Medicine
BackgroundFabry disease is a cardiomyopathy with multisystemic manifestations that is easily to be misdiagnosed as another type of cardiomyopathy.
Felycia Fernanda Hosyanto, Yuanzhu Li, Suxin Luo, Bi Huang   +3 more
doaj   +2 more sources

Emerging technologies for septal reduction therapy in hypertrophic cardiomyopathy [PDF]

Chinese Medical Journal
Yunye Zhang, Xingwei Zhang, Zhihong Zhao, Rongman Jia   +3 more
doaj   +2 more sources

Hypertrophic cardiomyopathy: state of the art on diagnosis and current therapeutic approach [PDF]

Cardiovascular Ultrasound
Background Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy and is characterized by unexplained myocardial hypertrophy. This condition exhibits marked clinical and prognostic heterogeneity.
Eluisa La Franca, Francesca Parisi, Alessandro Lucchino, Leyla Elif Sade, Tim Wong, Italia Loddo, Luigi Alioto, Giovanni Gentile, Michele Pilato, Manlio Cipriani, Francesco Fulvio Faletra   +10 more
doaj   +2 more sources